New immune cell combo aims to stop leukemia relapse

NCT ID NCT06152809

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-phase study tests whether giving specially trained immune cells (CIML NK cells) along with a targeted drug (venetoclax) can safely help prevent acute myeloid leukemia (AML) from coming back. Ten adults with AML who have already received standard treatment will receive the cell infusion plus supportive medications. The main goal is to check for side effects and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytokine-induced memory-like natural killer (CIML NK) cells, interleukin-2, and venetoclax
What this could lead to: If this works, it could offer a new consolidation option to help prevent AML relapse after initial treatment.
What could go wrong: This is a very early Phase 1 trial with only 10 participants, focused on safety. The combination may cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA RECURRENT LEUKEMIA LEUKEMIA, MYELOID

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.